HAEMATO AG Share Price Xetra

Equities

HAE

DE000A289VU3

Pharmaceuticals

End-of-day quote Xetra 23:00:00 04/02/2024 GMT 5-day change 1st Jan Change
26.2 EUR -0.76% Intraday chart for HAEMATO AG -1.50% -5.76%

Financials

Sales 2023 * 270M 288M 23.09B Sales 2024 * 281M 300M 24.06B Capitalization 112M 120M 9.58B
Net income 2023 * 7M 7.48M 599M Net income 2024 * 9M 9.62M 771M EV / Sales 2023 * 0.34 x
Net cash position 2023 * 21.3M 22.78M 1.82B Net cash position 2024 * 24.3M 25.98M 2.08B EV / Sales 2024 * 0.31 x
P/E ratio 2023 *
14.3 x
P/E ratio 2024 *
11.8 x
Employees -
Yield 2023 *
5.05%
Yield 2024 *
5.37%
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.4 EUR
Average target price
33 EUR
Spread / Average Target
+54.21%
Consensus

Quarterly revenue - Rate of surprise